Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Affymetrix and Singapore-based Start-up PathGEN Dx Sign Partnership

Published: Monday, August 27, 2012
Last Updated: Sunday, August 26, 2012
Bookmark and Share
Agreement for diagnostic test development for pathogen detection.

Affymetrix, Inc. and PathGEN Dx Pte. Ltd. have announced that they have signed a Powered by Affymetrix™ (PbA) Program agreement.

Under this PbA agreement, PathGEN Dx will develop an in-vitro diagnostic kit for comprehensive pathogen detection using their PathGEN® PathChip and is based on a patented, efficient, and accurate microarray-based protocol and analysis method.

The kit will be comprised of PathGEN Dx’s proprietary reagents, an automated software package, and a contract manufactured GeneChip® microarray from Affymetrix.

It will detect the presence of more than 70,000 viral and bacterial genomes from a wide variety of human samples, annotate the genomic information, and identify co-infecting pathogens.

Dr. Martin Hibberd, PathGEN Dx Co-Founder, said, “This will be the start of our development plan for a diagnostic microarray that we feel will ultimately help medical researchers and surveillance investigators identify the full range of viruses and bacteria in their samples.”

“We are very pleased to have PathGEN Dx join the Affymetrix’ PbA Program. This adds significantly to our PbA Program in which we help partners to develop novel molecular diagnostic tests that will potentially provide solutions for directing proper treatment for patients,” said Roger Schaller, Sr. Director of Global Business Development for Clinical Applications at Affymetrix.

“We are very proud that PathGEN Dx, the first spin-off from GIS, has achieved this collaboration that will significantly advance their reach to the clinical diagnostics global market. The journey first began in 2004 as a project in GIS, and then funded by Exploit Technologies in 2008 to clinically validate, productize, and develop the business strategy. This is an exciting next phase in PathGEN DX’s entrepreneurial journey and we look forward to greater success,” said Mr. Philip Lim, CEO of Exploit Technologies, A*STAR’s technology transfer arm.

“The Genome Institute of Singapore is pleased to support PathGEN Dx and look forward to incubating more startups in the future,” said Prof. Ng Huck Hui, Acting Executive Director of GIS.

This PbA Program agreement also provides PathGEN Dx access to Affymetrix’ international distribution network.

Dr. Christopher Wong, Founder of PathGEN Dx, added “We are pleased to join the ranks of other PbA Program partners, such as Roche Diagnostics and Pathwork Diagnostics in adopting the Affymetrix technology in our IVD product development program.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Affymetrix Reports 2013 First Quarter Results
Affymetrix, Inc. reported its operating results for the three months ended March 31, 2013.
Wednesday, May 01, 2013
Affymetrix Completes Acquisition of eBioscience Holding Company, Inc.
Acquisition expands Affymetrix’s addressable markets by more than $2.5 billion per year.
Thursday, June 28, 2012
Affymetrix Announces Research Collaboration with MGH
Collaboration and licensing agreement to validate and develop new oncology biomarker tests.
Thursday, June 07, 2012
Affymetrix to Acquire eBioscience
Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments. The transaction is subject to customary closing conditions.
Wednesday, December 14, 2011
Affymetrix to Acquire eBioscience
Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.
Saturday, December 03, 2011
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos